Last updated: September 23, 2021
Sponsor: West China Hospital
Overall Status: Active - Not Recruiting
Phase
3
Condition
Coronary Artery Disease
Congestive Heart Failure
Cardiovascular Disease
Treatment
N/AClinical Study ID
NCT04912167
WestChinaH-CVD-003
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged between 18 - 75 years old
- First-time ST-segment elevation myocardial infarction based on the newest ESCguidelines
- Timely primary percutaneous coronary intervention within 12 hours from onset
- Written informed consent acquired
Exclusion
Exclusion Criteria:
- Known history of or persistent clinical chronic heart failure prior to randomization
- Previous use of ARNI, or intolerance or contraindications to study drugs includingARNI or ACEI
- History of significant chronic coronary obstruction and adverse ventricular remodeling
- History of any cardiomyopathy, valvular heart disease, congenital heart disease, stentor CABG, or planned open-heart surgery within 3 months
- History of hepatic impairment or history of cirrhosis with evidence of portalhypertension
- History of chronic renal dysfunction, or eGFR < 30 ml/min/1.73 m2
- History of malignancy and with a life span less than one year
- Patients with a known history of angioedema related to previous ACEIs/ARB therapy.
- With contraindication to MRI examination (pacemaker and claustrophobia) or cannotfinish breath-holding when lying on the examination bed
- Pregnancy or nursing women
Study Design
Total Participants: 376
Study Start date:
November 01, 2021
Estimated Completion Date:
June 30, 2026
Connect with a study center
West China Hospital
Chengdu, Sichuan 621000
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.